XOMA Corp (XOMA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include X358, X213 and X129. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 (formerly LFA 102) is an allosteric inhibitor of prolactin action; X129 is a potent fragment of a monoclonal antibody with negative allosteric modulation activity. Xoma has developed its proprietary antibody discovery, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. Xoma is headquartered in Berkeley, California, the US.

XOMA Corp (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XOMA Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
XOMA Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XOMA Corp, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
XOMA to Acquire Assets from Enumeral Biomedical for USD1.6 Million 12
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 13
Private Equity 14
XOMA Sells Royalty Rights to HealthCare Royalty Partners 14
Partnerships 15
Domain Therapeutics Enters into Agreement with Xoma 15
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 16
Licensing Agreements 17
XOMA Enters into Licensing Agreement with AntriaBio 17
Tizona Therapeutics Enters into Licensing Agreement with XOMA 18
LakePharma Enters into Licensing Agreement with XOMA 19
Torch Biosciences Enters into Licensing Agreement with XOMA 20
PRLA Pharma Enters into Licensing Agreement with XOMA 21
Novartis Enters into Licensing Agreement with XOMA for Gevokizumab 22
Novartis Enters into Licensing Agreement with XOMA 23
Xoma Plans To Enter Into Licensing Agreement For Perindopril 24
Xoma Enters into Licensing Agreement with Texas A&M University System 25
Symplmed Pharma Enters Into Licensing Agreement With Xoma For Perindopril Franchise 26
XOMA Enters into Licensing Agreement with Margaux Biologics for BPI 27
Equity Offering 28
XOMA Files Registration Statement for Public Offering of Securities 28
Xoma Raises USD25 Million in Registered Direct Offering of Shares 29
Xoma Raises USD40 Million in Private Placement of Shares and Warrants 30
Xoma Completes Public Offering Of Shares For US$57.4 Million 32
Xoma Completes Public Offering Of Shares For US$31.6 Million 34
Xoma Completes Public Offering Of Shares For US$40 Million 35
XOMA Completes Public Offering Of Common Stock For US$39 Million 37
Asset Transactions 39
Agenus Acquires Antibody Manufacturing Facilities from XOMA 39
Nanotherapeutics Ammends agreement with XOMA 41
CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 42
XOMA Corp - Key Competitors 43
XOMA Corp - Key Employees 44
XOMA Corp - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 46
Financial Announcements 46
May 09, 2018: XOMA Reports First Quarter 2018 Financial Results 46
Mar 07, 2018: XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 47
Nov 06, 2017: XOMA Reports Third Quarter 2017 Financial Results 49
Aug 08, 2017: XOMA Reports Second Quarter 2017 Financial Results 51
May 09, 2017: XOMA Reports First Quarter 2017 Financial Results 52
Mar 16, 2017: XOMA Reports Fourth Quarter and Full Year 2016 Financial Results 53
Corporate Communications 55
Feb 16, 2017: XOMA Appoints Matthew Perry to its Board of Directors 55
Product News 56
03/23/2017: XOMA Provides Update On New Drug Candidate At The 2017 ENDO Meeting 56
Clinical Trials 57
Apr 18, 2017: XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program 57
Mar 28, 2017: XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting 58
Other Significant Developments 59
Jun 26, 2018: XOMA Added to the Russell 2000 and Russell 3000 Indexes 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List Of Tables

List of Tables
XOMA Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XOMA Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XOMA Corp, Deals By Therapy Area, 2012 to YTD 2018 9
XOMA Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XOMA to Acquire Assets from Enumeral Biomedical for USD1.6 Million 12
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 13
XOMA Sells Royalty Rights to HealthCare Royalty Partners 14
Domain Therapeutics Enters into Agreement with Xoma 15
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 16
XOMA Enters into Licensing Agreement with AntriaBio 17
Tizona Therapeutics Enters into Licensing Agreement with XOMA 18
LakePharma Enters into Licensing Agreement with XOMA 19
Torch Biosciences Enters into Licensing Agreement with XOMA 20
PRLA Pharma Enters into Licensing Agreement with XOMA 21
Novartis Enters into Licensing Agreement with XOMA for Gevokizumab 22
Novartis Enters into Licensing Agreement with XOMA 23
Xoma Plans To Enter Into Licensing Agreement For Perindopril 24
Xoma Enters into Licensing Agreement with Texas A&M University System 25
Symplmed Pharma Enters Into Licensing Agreement With Xoma For Perindopril Franchise 26
XOMA Enters into Licensing Agreement with Margaux Biologics for BPI 27
XOMA Files Registration Statement for Public Offering of Securities 28
Xoma Raises USD25 Million in Registered Direct Offering of Shares 29
Xoma Raises USD40 Million in Private Placement of Shares and Warrants 30
Xoma Completes Public Offering Of Shares For US$57.4 Million 32
Xoma Completes Public Offering Of Shares For US$31.6 Million 34
Xoma Completes Public Offering Of Shares For US$40 Million 35
XOMA Completes Public Offering Of Common Stock For US$39 Million 37
Agenus Acquires Antibody Manufacturing Facilities from XOMA 39
Nanotherapeutics Ammends agreement with XOMA 41
CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 42
XOMA Corp, Key Competitors 43
XOMA Corp, Key Employees 44
XOMA Corp, Subsidiaries 45

List Of Figures

List of Figures
XOMA Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XOMA Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

XOMA Corp (XOMA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety

USD 250 View Report

XOMA Corporation Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

XOMA Corporation Company Profile is a detailed strategic and analytical report on XOMA Corporation. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

XOMA Corporation Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

XOMA Corporation Company Profile is a detailed strategic and analytical report on XOMA Corporation. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review

XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available